Q8. SCOPING QUESTION: In people with bipolar disorders who require maintenance treatment, are a) antipsychotics or b) mood stabilizers (lithium, valproate or carbamazepine) effective and safe?
Other disorders
Chapter H.5.1
Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?
Otros trastornos
Capítulo H.5.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Iván Olle Llopis
Q5.SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment, what is the safety and role of depot antipsychotic medication?
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Q2: In individuals with psychotic disorders (including schizophrenia), is the use of two or more antipsychotic medications concurrently more effective and safer than the use of one antipsychotic only?
Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Ukrainian Title:
УКРАЇНА: Еквівалентність лікарських засобів, зареєстрованих в Україні та інших країнах. Інформація для працівників охорони здоров'я та пацієнтів
To support t...he provision of healthcare and medicines in the host countries, and as part of FIP’s response to the appeals of our member organisation, the All-Ukrainian Pharmaceutical Chamber, FIP has developed the tables of equivalence between medicines registered in Ukraine and those available in other countries, published in this document. This is meant to facilitate the provision of (pharmaceutical) care to refugees and also to support healthcare professionals providing care to them. We are
prioritising medicines for the following chronic non-communicable diseases that require continuation of treatment: asthma & COPD, mental health, cardiovascular diseases and diabetes, but also oral contraceptives. This list may be expanded as necessary.
more
Int Nurs Rev. 2018 Mar;65(1):78-92. doi: 10.1111/inr.12391. Epub 2017 May 25.
Обнаружили улучшение изучаемого показателя в группе первичных пациентов, получающих лечение атипичными нейролептиками в сочетании с реабилитацией. Полученные д...нные позволяют сделать вывод о влиянии длительности заболевания, наблюдения, а также характера проводимой терапии на изменчивость показателя эмоционального интеллекта у пациентов с параноидной формой шизофрении и могут быть использованы для выбора психотерапевтического алгоритма для данной категории больных. http://www.ssmj.ru/system/files/2017_04_834-838.pdf
more
Sci Rep. 2016; 6: 25920. Published online 2016 May 16. doi: 10.1038/srep25920